R&D

Upperton Pharma Solutions, a contract and development manufacturing organisation (CDMO) based in the north of England, UK, has announced the expansion of its 50,000ft2 site Trent Gateway with the newly-completed £7m sterile manufacturing facility.

The facility was designed specifically with revised EU good manufacturing practice (GMP) Annex-1regulations at the forefront of the design. Spanning 7,000ft2 , the facility has the capability to enable clinical manufacture and analytical testing. Up to 2,000 vials, pre-filled syringes, pre-filled cartridges for liquid formulations and pre-sterilised powders could be manufactured at a time in the plant, according to the press release.

In addition to this, the facility also has capacity for supporting formulation development. Two cleanrooms in the sterile facility will feature advanced vaporised hydrogen peroxide (VHP) isolation technology, further enabling the facility to ensure that manufacturing of sterile products follows GMP.

Nikki Whitfield, chief executive officer, said, “We are delighted to complete the build of our sterile facility. The combined experience of our leadership team in sterile facility builds and subsequent operations ensures that we are ideally placed as a CDMO partner of choice for small to mid-sized biotech and pharma looking to get into the clinic quickly with fast access to sterile manufacturing services.”